Qualigen Therapeutics Inc (QLGN) News
Filter QLGN News Items
QLGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
QLGN News Highlights
- For QLGN, its 30 day story count is now at 8.
- Over the past 19 days, the trend for QLGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG, GLP and ROSE are the most mentioned tickers in articles about QLGN.
Latest QLGN News From Around the Web
Below are the latest news stories about QUALIGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate QLGN as an investment opportunity.
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the initiation of Good Laboratory Practice (GLP) toxicology studies of its lead oncology program, QN-302, a G4-selective transcription inhibitor currently in development for |
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate CommunicationsQualigen Therapeutics, Inc. Benedict M. Abugan CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the promotion of Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications. Mr. Abugan has over tw |
Why Qualigen Therapeutics Inc. (NASDAQ: QLGN) Is A Stock Not To Be Discarded In 2023In the last trading session, 0.14 million shares of the Qualigen Therapeutics Inc. (NASDAQ:QLGN) were traded, and its beta was -0.41. Most recently the company’s share price was $1.34, and it changed around -$0.04 or -2.90% from the last close, which brings the market valuation of the company to $5.80M. QLGN currently trades at a … Why Qualigen Therapeutics Inc. (NASDAQ: QLGN) Is A Stock Not To Be Discarded In 2023 Read More » |
Qualigen Therapeutics Inc. (QLGN) can beat the pack with these strategiesAs of Monday, Qualigen Therapeutics Inc.’s (NASDAQ:QLGN) stock closed at $1.27, down from $1.43 the previous day. While Qualigen Therapeutics Inc. has underperformed by -11.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, QLGN fell by -88.35%, with highs and lows ranging from $15.20 to $1.11, […] |
Qualigen stock soars 15% on FDA orphan drug status for pancreatic cancer therapyQualigen Therapeutics (QLGN) stock rose ~20% on Tuesday after the company said that the U.S |
Qualigen Therapeutics Inc. (NASDAQ: QLGN) Is The Most Intriguing Stock Today.In the last trading session, 3.82 million Qualigen Therapeutics Inc. (NASDAQ:QLGN) shares changed hands as the company’s beta touched -0.44. With the company’s per share price at $1.27 changed hands at -$0.16 or -11.19% during last session, the market valuation stood at $5.69M. QLGN’s last price was a discount, traded about -1096.85% off its 52-week … Qualigen Therapeutics Inc. (NASDAQ: QLGN) Is The Most Intriguing Stock Today. Read More » |
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic CancerCARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead drug candidate, QN-302, for the indication of Pancreatic Cancer. QN-302 |
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic PlatformCARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, NanoSynex Ltd. (“NanoSynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its i |
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleCARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance |
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid TumorsCARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received feedback from the FDA following a pre-Investigational New Drug (pre-IND) interaction regarding the development pathway to a Phase 1 clinical trial of QN- |